NCT07326566Phase 2Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Study sponsor: Black Diamond Therapeutics, Inc. · BDTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-11Estimated
Enrollment · participants162Estimated
Source updated2026-11-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source